American Journal of Medicine: Introduction and overview

American Journal of Medicine

Volumn 110, Issue 7, 2001, Pages

  Gheorghiade, Mihai ^a   Bonow, Robert O ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLOSEQUINAN; INOTROPIC AGENT; MIBEFRADIL; MILRINONE; NITRATE; PROSTACYCLIN; VASODILATOR AGENT; XAMOTEROL;

CONGESTIVE HEART FAILURE; HEART EJECTION FRACTION; HUMAN; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUDDEN DEATH; SYMPTOMATOLOGY;

EID: 0035821278     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Survival after the onset of congestive heart failure in Framingham Heart Study subjects
2. Guidelines for the evaluation and management of heart failure: Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
3. Changes in risk factors and the decline in mortality from cardiovascular disease: The Framingham Heart Study
4. Trends in hospitalization rates for heart failure in the United States, 1973-1986: Evidence for increasing population prevalence
5. National health expenditures, 1990
6. Heart and Stroke Facts
7. Epidemiological aspects of heart failure
8. Economic impact of heart failure in the United States: Time for a different approach
9. National history and patterns of current practice in heart failure
10. Chronic heart failure in the United States: A manifestation of coronary artery disease
11. Prevalence, clinical features, and prognosis of diastolic heart failure: An epidemiologic perspective
12. Systolic function, readmission rates, and survival among consecutively hospitalized congestive heart failure patients
13. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial
14. Pharmacotherapy for systolic dysfunction: A review of randomized clinical trials
15. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
16. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
17. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
18. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
19. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial
20. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
21. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
22. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
23. The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial
24. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
25. Pathophysiology of heart failure
26. Consensus recommendations for the management of chronic heart failure
27. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria
28. Reliability of bedside evaluation in determining left ventricular function: Correlation with left ventricular ejection fraction determined by radionuclide ventriculography
29. Current medical therapy for advanced heart failure
30. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: Assessment by a bilateral intracoronary infusion technique
31. The pathophysiology of advanced heart failure
32. The role of the neurohormonal system in heart failure
33. Rationale for the use of chronic adrenergic blockade in patients with chronic heart failure
34. The dysfunctional endothelium in heart failure
35. Sudden death prevention in patients with advanced ventricular dysfunction
36. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure
37. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
38. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade
39. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure